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Objectives: To compare the use of co-medication, the potential drug–drug interactions (PDDIs) and the effect
on antiretroviral therapy (ART) tolerability and efficacy in HIV-infected individuals according to age, ≥50 years
or ,50 years.
Methods: All ART-treated participants were prospectively included once during a follow-up visit of the Swiss HIV
Cohort Study. Information on any current medication was obtained by participant self-report and medical pre-
scription history. The complete treatment was subsequently screened for PDDIs using a customized version of
the Liverpool drug interaction database.
Results: Drug prescriptions were analysed for 1497 HIV-infected individuals: 477 age ≥50 and 1020 age ,50.
Older patients were more likely to receive one or more co-medications compared with younger patients (82%
versus 61%; P,0.001) and thus had more frequent PDDIs (51% versus 35%; P,0.001). Furthermore, older
patients tended to use a higher number of co-medications and certain therapeutic drug classes more often,
such as cardiovascular drugs (53% versus 19%; P,0.001), gastrointestinal medications (10% versus 6%;
P¼0.004) and hormonal agents (6% versus 3%; P¼0.04). PDDIs with ART occurred mainly with cardiovascular
drugs (27%), CNS agents (22%) and methadone (6%) in older patients and with CNS agents (27%), methadone
(15%) and cardiovascular drugs (11%) in younger patients. The response to ART did not differ between the two
groups.
Conclusions: The risk for PDDIs with ART increased in older patients who take more drugs than their younger
HIV-infected counterparts. However, medication use in older and younger patients did not differ in terms of
effect on antiretroviral tolerability and response.
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Introduction
HIV-infected individuals are becoming older as a result of
reduced AIDS-related mortality due to combination antiretroviral
therapy (ART).1 It is projected that by 2015, more than half of all
HIV-infected individuals in the USA will be ≥50 years of age.2
Compared with age-matched HIV-uninfected individuals and
with younger HIV-infected individuals, HIV-infected people
≥50 years have a higher rate of co-morbidities such as cardio-
vascular disease, metabolic disorders, osteoporosis, non-HIV
cancers, hepatic and renal impairments, possibly exacerbated
by HIV infection or long-term exposure to ART.3 Consequently,
the management of HIV infection in older patients is compli-
cated by polypharmacy, which may increase the rate of potential
drug–drug interactions (PDDIs) with antiretroviral therapy as well
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as drug toxicity.4 Our aim was to compare the use of
co-medication, the risk for PDDIs and the effect on ART tolerabil-
ity and virological suppression in older versus younger
HIV-infected individuals.
Methods
The data for this analysis were collected in the framework of a cross-
sectional study aimed at investigating the prevalence of PDDIs among
the patients of the Swiss HIV Cohort Study (SHCS).5 Briefly, the study pro-
spectively included all ART-treated patients scheduled for an SHCS
follow-up visit once from April 2008 to January 2009. Information on
current medication was obtained by patient self-report and medical pre-
scription history. The drugs documented included ART, co-medications
used for opportunistic infections and concurrent diseases, as well as self-
prescribed drugs, herbals and recreational drugs. The complete
treatment was screened for PDDIs using a customized version of the Uni-
versity of Liverpool drug interaction database,6 and interactions were
subsequently validated by two experts in HIV pharmacology. The Liver-
pool drug interaction database features interactive charts to assess the
risk of drug interactions between HIV–HIV drugs and HIV–non-HIV
drugs. These charts rank the clinical significance of an interaction from
‘no interaction’ to ‘dose adaptation’ and ‘contraindicated’.6
Potentially clinically relevant drug interactions were defined as all
drug interactions involving an HIV drug and requiring dose adjustment
or contraindicated drug combinations. Conversely, drug interactions
were not counted as clinically significant if the appropriate dose adap-
tation had already been performed, if the change in pharmacokinetic
parameters was less than 25% and/or if the interaction was reported
as clinically irrelevant. Interactions between non-HIV medications were
excluded from this analysis.
Information on socio-demographic characteristics, data on the clini-
cal course, co-infection with hepatitis B or C, immunological and viral par-
ameters were extracted from the SHCS database at the time of
co-medication assessment. Additional data on the virological and
immunological outcomes as well as the rate of treatment change or dis-
continuation because of toxicity or adverse events were obtained after
6–12 months of follow-up. Viral suppression was defined as an HIV
viral load of ,50 copies/mL.
The SHCS was approved by the relevant ethics committees of the par-
ticipating centres, and written consent was obtained from all study
participants.
For the statistical analysis, patients were grouped as ‘older patients’
(≥50 years) and ‘younger patients’ (,50 years) based on the CDC defi-
nition of older HIV patients.7 Basic socio-demographic characteristics,
CD4 cell count, HIV viral load, ART regimens and co-medication were
compared using the x2 test or Fisher’s exact test for categorical variables,
and the Mann–Whitney test for continuous variables. All analyses were
performed using STATA software version 11 for Windows.
Results
The analysis included 1497 ART-treated patients, among whom
477 (32%) and 1020 (68%) were ≥50 years and ,50 years,
respectively. Older and younger patients differed in terms of
socio-demographic characteristics, mode of HIV transmission,
co-infection and use of co-medication (Table 1). Older HIV
patients were more likely to be male, Caucasian and have a
higher body mass index. Men having sex with men (MSM) was
the main mode of HIV transmission in the group of older
patients. The presence of a prior AIDS-defining condition and
pre-treatment with antiretroviral therapy were more common
in older patients. A higher percentage of drug addiction and
co-infection with hepatitis C virus (HCV) was observed in the
group of younger HIV patients. The median CD4 cell count and
the percentage of patients virally suppressed did not differ sub-
stantially between older and younger HIV patients (493 versus
513 cells/mm3; P¼0.126 and 87% versus 84%; P¼0.062,
respectively).
Older HIV patients were more likely to receive one or
more co-medications compared with younger patients [82%
Table 1. General characteristics of the study population (n¼1497)
according to age
Characteristics
Age ,50 years
(n¼1020)
Age ≥50 years
(n¼477) P
Males 625 (61) 383 (80) ,0.001
Median body mass index,
kg/m2 (IQR)
23 (21–26) 24 (22–26) ,0.001
Non-white ethnicity 263 (26) 25 (5) ,0.001
Transmission risk
MSM 293 (29) 209 (44) ,0.001
heterosexual 466 (46) 196 (41)
IDU 261 (26) 72 (15)
Current IDU 43 (4) 8 (2) 0.012
Current recreational drug
use
216 (21) 48 (10) ,0.001
Prior AIDS-defining
condition
281 (28) 156 (33) 0.041
Education
low 334 (33) 87 (18) ,0.001
middle 444 (44) 238 (50)
high 226 (22) 143 (30)
HCV co-infection 297 (29) 88 (19) ,0.001
HBV co-infection
(HBs-antigen positive)
43 (4) 29 (6) 0.116
ART naive 133 (13) 40 (8) 0.009
Co-medication 624 (61) 389 (82) ,0.001
Interaction 357 (35) 242 (51) ,0.001
Median CD4 cell count,
cells/mm3 (IQR)
513 (361–702) 493 (355–658) 0.126
HIV RNA ,50 copies/mL 853 (84) 417 (87) 0.062
Class
PI 507 (50) 186 (39) ,0.001
NNRTI 367 (36) 207 (43)
PI+NNRTI 57 (6) 40 (8)
other 89 (9) 44 (9)
Backbone
TDF/FTC or TDF/3TC 417 (41) 188 (39) 0.302
ABC/3TC 194 (19) 78 (16)
ZDV/3TC 126 (12) 63 (13)
other 185 (18) 103 (22)
ABC, abacavir; 3TC, lamivudine; FTC, emtricitabine; TDF, tenofovir; ZDV,
zidovudine; IDU, intravenous drug user; IQR, interquartile range.
Data are presented as number (%) of patients, unless otherwise
indicated.
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(389/477) versus 61% (624/1020); P,0.001] and thus had more
frequent PDDIs [51% (242/477) versus 35% (357/1020);
P,0.001] (Table 1). Furthermore, older patients tended to use
a higher number of co-medications {median number of
co-medications 2 [interquartile range (IQR) 1–4)] versus 1 [IQR
0–2]} (Figure 1a) and certain therapeutic drug classes more
often than younger patients (Figure 1b), such as cardiovascular
drugs (53% versus 19%; P,0.001), gastrointestinal medications
(10% versus 6%; P¼0.004) and hormonal agents (6% versus 3%;
P¼0.04). Conversely, younger patients more often received
methadone (10% versus 6%; P¼0.002). No differences in use
of CNS agents, anti-infectives and analgesics were seen
between the two groups (Figure 1b).
Among the older patients with co-medication, PDDIs were
mainly between protease inhibitors (PIs) or non-nucleoside
reverse transcriptase inhibitors (NNRTIs) and cardiovascular
0
10
20
30
40
50
0 1 2 3 4 5 6 7 >8
Number of co-medications
Pa
tie
nt
s 
(%
)
<50 years
≥50 years
(a)
Ca
rdi
ov
as
cu
lar
 dr
ug
s
CN
S a
ge
nt
s
An
ti-
inf
ec
tiv
es
An
alg
es
ics
Ga
str
oin
tes
tin
al 
dru
gs
Me
th
ad
on
e
Ho
rm
on
es
An
tili
pid
em
ics
≥50 years
0
10
20
30
40
50
60
An
tip
lat
ele
ts/
an
tic
oa
gu
lan
ts
AC
E i
nh
ibi
tor
s
Be
ta 
blo
ck
ers
An
gio
ten
sin
 II
 in
hib
ito
rs
Diu
ret
ics
In
su
lin
/an
tid
iab
eti
cs
Ca
lci
um
 ch
an
ne
l in
hib
ito
rs
Pa
tie
nt
s 
(%
)
<50 years
(b)
*
** **
***
***
***
***
*** *** *** ***
***
Figure 1. Number of co-medications (a) and therapeutic drug classes (b) used in patients age ,50 years or ≥50 years. (b) Each bar represents the
percentage of patients using one or more drugs of the corresponding therapeutic class. Detailed use of cardiovascular drugs is presented in the
right-hand half of the figure. CNS agents included anxiolytics/sedatives, antidepressants, antipsychotics and anticonvulsants. Anti-infectives
included antibacterials, antivirals, antifungals and antimycobacterials. Analgesics included anti-inflammatory drugs, paracetamol and narcotic
analgesics. Gastrointestinal drugs included proton pump inhibitors, antidiarrhoea drugs and H2 blockers. *P,0.05, **P,0.01, ***P,0.001.
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drugs (27%), CNS agents (22%) and methadone (6%). Among
the younger patients with co-medication, PDDIs occurred
mainly between CNS agents (27%), methadone (15%) and cardi-
ovascular drugs (11%). In the majority of PDDIs the antiretroviral
affected the co-medication rather than the co-medication
affecting the antiretroviral. Therefore, there was no difference
in virological suppression (90% in older and 85% in younger sub-
jects with PDDIs; P¼0.093).
A change in ART because of toxicity, defined as any clinical
or serious laboratory adverse events, was performed in 4% of
older versus 3% of younger patients with PDDIs (P¼0.374).
The type of toxicity was similar in both groups (P¼0.314)
and was mostly characterized by gastrointestinal intolerance,
followed by CNS-related side effects, hepatotoxicity and
dyslipidaemia.
Discussion
Little is known about the impact of ageing on medication use in
HIV-infected patients, the potential interactions of
co-medications with ART and the effect on antiretroviral
therapy tolerability and virological outcome. We found that the
risk for PDDIs increases in older patients who take more drugs
than their younger HIV-infected counterparts. In the present
study, certain therapeutic classes, mainly cardiovascular drugs,
and to a lesser extent gastrointestinal and hormonal agents,
were more often used in older patients, in agreement with pre-
vious surveys from Italy and Canada.8 – 10 The higher proportion
of cardiovascular drugs in older patients may result from pro-
longed exposure to ART, which has been correlated with
increased cardiovascular risk.11 In addition, age constitutes an
important risk factor for the development of metabolic disorders
and, ultimately, for increased cardiovascular risk.
Since PDDIs were primarily related to ART acting on the
co-medication,5 no adverse effects were noted on ART tolerabil-
ity or efficacy. This suggests that specific therapeutic drug
classes used in elderly patients were not per se a risk factor for
impaired response to ART.
Besides medication use, older and younger patients differed
in terms of mode of HIV infection. The higher rate of HIV
transmission through homosexual contacts observed in older
patients may be explained by the fact that HIV infection
was more prevalent among MSM in the early years of the
epidemic.
Our study has some limitations. The dose or eventual dose
adjustment of co-medications was not systematically reported,
which may have influenced the tolerability results. Toxicities
resulting from PDDIs were not assessed through laboratory
abnormalities. However, we considered all side effects that
were serious enough to require a treatment change. The cross-
sectional design of the study did not allow us to determine
whether co-morbidities were present before HIV infection or
developed during the course of the disease or following initiation
of antiretroviral therapy.
With the ever-increasing number of older patients, future
research will be instrumental in addressing issues of drug–drug
interactions, risk of toxicity and the impact of polypharmacy on
adherence.
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